Cargando…
PSAT267 Performance of ThyroSeq V3 molecular testing in assessing indeterminate thyroid nodules for thyroid cancer at an urban endocrinology clinic.
INTRODUCTION: While fine needle aspiration (FNA) biopsy can accurately classify thyroid nodules as benign versus malignant in most cases, roughly 20% of cases remain indeterminate. Molecular testing can assist with risk stratification of indeterminate nodules, with the goal to identify benign nodule...
Autores principales: | Bao, Ginny, Chang, Christine, Yin, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625561/ http://dx.doi.org/10.1210/jendso/bvac150.1675 |
Ejemplares similares
-
MON-570 Clinical Utility of ThyroSeq v3 Genomic Classifier Test in Detecting Gene Fusions in Thyroid Nodules
por: Nikiforova, Marina, et al.
Publicado: (2019) -
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
por: Nikiforov, Yuri E., et al.
Publicado: (2019) -
Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology
por: Nikiforov, Yuri E., et al.
Publicado: (2015) -
Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making
por: Kargi, Atil Y., et al.
Publicado: (2017) -
Surgical Outcomes of Thyroid Nodules Positive for Gene Expression Alterations Using ThyroSeq V3 Genomic Classifier
por: Salameh, Samer, et al.
Publicado: (2022)